Reviewed,
UniProtKB/Swiss-Prot Q00987 (MDM2_HUMAN)
Last modified
November 25, 2008.
Version 120.
History...
Clusters with 100%,
90%,
50% identity |
Documents (4) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: E3 ubiquitin-protein ligase Mdm2 EC=6.3.2.- Alternative name(s): p53-binding protein Mdm2 Oncoprotein Mdm2 Double minute 2 protein Hdm2 | ||
| Gene names |
| ||
| Organism | Homo sapiens (Human) | ||
| Taxonomic identifier | 9606 [NCBI] | ||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 491 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Inhibits TP53/p53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Functions as a ubiquitin ligase E3, in the presence of E1 and E2, toward p53 and itself. Permits the nuclear export of p53 and targets it for proteasome-mediated proteolysis. |
| Subunit structure | Binds p53, p73, ARF(P14), ribosomal protein L5 and specifically to RNA. Can interact also with retinoblastoma protein (RB), E1A-associated protein EP300 and the E2F1 transcription factor. Forms a ternary complex with TP53/p53 and WWOX. Interacts with CDKN2AIP, MTBP, TBRG1, USP7, PYHIN1 and UBXN6. Isoform Mdm2-F does not interact with TP53/p53. Interacts with and ubiquitinates HIV-1 Tat. |
| Subcellular location | Nucleus › nucleoplasm. Cytoplasm. Nucleus › nucleolus. Note= Expressed predominantly in the nucleoplasm. Interaction with ARF(P14) results in the localization of both proteins to the nucleolus. The nucleolar localization signals in both ARF(P14) and MDM2 may be necessary to allow efficient nucleolar localization of both proteins. |
| Tissue specificity | Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B, isoform Mdm2-C, isoform Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and isoform Mdm2-G are observed in a range of cancers but absent in normal tissues. |
| Induction | By DNA damage. |
| Domain | Region I is sufficient for binding p53 and inhibiting its G1 arrest and apoptosis functions. It also binds p73 and E2F1. Region II contains most of a central acidic region required for interaction with ribosomal protein L5 and a putative C4-type zinc finger. The RING finger domain which coordinates two molecules of zinc interacts specifically with RNA whether or not zinc is present and mediates the heterooligomerization with MDM4. It is also essential for its ubiquitin ligase E3 activity toward p53 and itself. |
| Post-translational modification | Phosphorylated in response to ionizing radiation in an ATM-dependent manner. Auto-ubiquitinated; which leads to proteasomal degradation. |
| Involvement in disease | Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. |
| Miscellaneous | MDM2 RING finger mutations that failed to ubiquitinate p53 in vitro did not target p53 for degradation when expressed in cells. |
| Sequence similarities | Belongs to the MDM2/MDM4 family. Contains 1 RanBP2-type zinc finger. Contains 1 RING-type zinc finger. Contains 1 SWIB domain. |
Ontologies
Binary interactions
Alternative products
| This entry describes 10 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform Mdm2 (identifier: Q00987-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform Mdm2-A (identifier: Q00987-2) The sequence of this isoform differs from the canonical sequence as follows: 28-222: Missing. | ||||||
| Isoform Mdm2-A1 (identifier: Q00987-3) The sequence of this isoform differs from the canonical sequence as follows: 28-222: Missing. 275-300: Missing. | ||||||
| Isoform Mdm2-B (identifier: Q00987-4) The sequence of this isoform differs from the canonical sequence as follows: 28-300: Missing. | ||||||
| Isoform Mdm2-C (identifier: Q00987-5) The sequence of this isoform differs from the canonical sequence as follows: 53-222: Missing. | ||||||
| Isoform Mdm2-D (identifier: Q00987-6) The sequence of this isoform differs from the canonical sequence as follows: 30-388: Missing. | ||||||
| Isoform Mdm2-E (identifier: Q00987-7) The sequence of this isoform differs from the canonical sequence as follows: 76-102: YCSNDLLGDLFGVPSFSVKEHRKIYTM → NDCANLFPLVDLSIRELYISNYITLGI 103-491: Missing. | ||||||
| Isoform Mdm2-alpha (identifier: Q00987-8) The sequence of this isoform differs from the canonical sequence as follows: 1-61: Missing. | ||||||
| Isoform Mdm2-F (identifier: Q00987-9) The sequence of this isoform differs from the canonical sequence as follows: 53-97: Missing. | ||||||
| Isoform Mdm2-G (identifier: Q00987-10) The sequence of this isoform differs from the canonical sequence as follows: 115-169: Missing. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 491 | 491 | E3 ubiquitin-protein ligase Mdm2 | PRO_0000157332 | |||||||||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||||||||
| Domain | 27 – 107 | 81 | SWIB | ||||||||||||||||||||||||||||||||||||||||||
| Zinc finger | 299 – 328 | 30 | RanBP2-type | ||||||||||||||||||||||||||||||||||||||||||
| Zinc finger | 438 – 479 | 42 | RING-type | ||||||||||||||||||||||||||||||||||||||||||
| Region | 150 – 230 | 81 | Interaction with PYHIN1 | ||||||||||||||||||||||||||||||||||||||||||
| Region | 170 – 306 | 137 | Interaction with MTBP By similarity | ||||||||||||||||||||||||||||||||||||||||||
| Region | 210 – 304 | 95 | ARF-binding | ||||||||||||||||||||||||||||||||||||||||||
| Region | 223 – 232 | 10 | Interaction with USP7 | ||||||||||||||||||||||||||||||||||||||||||
| Region | 242 – 331 | 90 | Region II | ||||||||||||||||||||||||||||||||||||||||||
| Motif | 179 – 185 | 7 | Nuclear localization signal Potential | ||||||||||||||||||||||||||||||||||||||||||
| Motif | 190 – 202 | 13 | Nuclear export signal | ||||||||||||||||||||||||||||||||||||||||||
| Motif | 466 – 473 | 8 | Nucleolar localization signal Potential | ||||||||||||||||||||||||||||||||||||||||||
| Compositional bias | 210 – 215 | 6 | Poly-Ser | ||||||||||||||||||||||||||||||||||||||||||
| Compositional bias | 243 – 301 | 59 | Asp/Glu-rich (acidic) | ||||||||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 1 – 61 | 61 | Missing in isoform Mdm2-alpha. | VSP_003207 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 28 – 300 | 273 | Missing in isoform Mdm2-B. | VSP_003209 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 28 – 222 | 195 | Missing in isoform Mdm2-A and isoform Mdm2-A1. | VSP_003208 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 30 – 388 | 359 | Missing in isoform Mdm2-D. | VSP_003210 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 53 – 222 | 170 | Missing in isoform Mdm2-C. | VSP_003211 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 53 – 97 | 45 | Missing in isoform Mdm2-F. | VSP_022578 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 76 – 102 | 27 | YCSND…KIYTM → NDCANLFPLVDLSIRELYIS NYITLGI in isoform Mdm2-E. | VSP_003212 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 103 – 491 | 389 | Missing in isoform Mdm2-E. | VSP_003213 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 115 – 169 | 55 | Missing in isoform Mdm2-G. | VSP_022579 | |||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 275 – 300 | 26 | Missing in isoform Mdm2-A1. | VSP_003214 | |||||||||||||||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 305 | 1 | C → S: No loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 374 | 1 | C → T: No loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 438 | 1 | C → L: No loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 441 | 1 | C → G: Fails to interact with MDM4 | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 449 | 1 | C → A: Loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 449 | 1 | C → S: No substantial decrease of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 452 | 1 | H → A: Loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 455 | 1 | T → A: Significant decrease of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 457 | 1 | H → S: Loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 461 | 1 | C → S: Loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 464 | 1 | C → A: Loss of ubiquitin ligase E3 activity, enhances protein stability | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 475 | 1 | C → G: Loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 478 | 1 | C → R: Fails to interact with MDM4 | ||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 478 | 1 | C → S: Loss of ubiquitin ligase E3 activity | ||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 17 | 1 | S → P in AAA82237. Ref.7 | ||||||||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 9 – 12 | 4 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 27 – 30 | 4 | |||||||||||||||||||||||||||||||||||||||||||
| Helix | 32 – 40 | 9 | |||||||||||||||||||||||||||||||||||||||||||
| Helix | 50 – 64 | 15 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 71 – 76 | 6 | |||||||||||||||||||||||||||||||||||||||||||
| Helix | 81 – 86 | 6 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 87 – 92 | 6 | |||||||||||||||||||||||||||||||||||||||||||
| Helix | 96 – 104 | 9 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 107 – 109 | 3 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 295 – 297 | 3 | |||||||||||||||||||||||||||||||||||||||||||
| Helix | 299 – 301 | 3 | |||||||||||||||||||||||||||||||||||||||||||
| Turn | 306 – 308 | 3 | |||||||||||||||||||||||||||||||||||||||||||
| Turn | 320 – 322 | 3 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 433 – 436 | 4 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 439 – 444 | 6 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 446 – 461 | 16 | |||||||||||||||||||||||||||||||||||||||||||
| Helix | 462 – 470 | 9 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 476 – 479 | 4 | |||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 482 – 490 | 9 | |||||||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||||||||

Clusters with